Tuesday, August 4, 2026

Foreign selling may slow as earnings improve, says Valentis Advisors’ Jyotivardhan Jaipuria

Date:

Jyotivardhan Jaipuria, Founder and Managing Director of Valentis Advisors, said tariff-linked stocks are facing renewed pressure as hopes of a trade deal fade, while the broader market could find support from earnings recovery and a slowdown in foreign selling.Jaipuria believes this year will be better than last year for equities, helped by an earnings recovery. After several quarters of single-digit growth, he sees the potential for double-digit earnings growth over the next few quarters.

He also sees foreign institutional investors (FIIs) turning buyers later this year given that India underperformed the MSCI Emerging Markets Index last year and relative valuations are now closer to long-term averages.

“FIIs will sell less,” he said, adding that this shift could help the market through the year.Among sectors, Jaipuria expects metals to perform over the next 12 to 18 months despite volatility. He cited recent safeguard duties on hot-rolled coils as a factor that may support domestic producers. “It’s a space where investors will make money,” he said, noting that protectionist measures could help the sector this year.

Also Read |

Emmer Capital CEO explains what could revive foreign investor interest in 2026

Also Read | Bay Capital sees credit growth driving banks, stays selective on tech and metals

On information technology stocks, including TCS and Infosys, Jaipuria said he does not expect a strong recovery. He pointed to structural issues linked to artificial intelligence that could keep growth weak for several years.

He said Valentis Advisors remains underweight on IT and views any buying as tactical rather than long-term.

Jaipuria said chemicals and pharmaceuticals are areas to watch selectively. While the broader chemicals sector still faces challenges from China competition, he said stock-specific triggers such as new capacity or export benefits could drive earnings. He added that pharma stocks, which have underperformed for a long period, are now at levels where pessimism may already be priced in.

For the full interview, watch the accompanying video

Catch all the latest updates from the stock market here

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

India hikes windfall tax on fuel exports; No impact on domestic retail prices

The Centre has increased the Special Additional Excise Duty...

Piyush Goyal says India can explore FTA with Uzbekistan, seeks to double trade in 3 years

India can explore negotiating a free trade agreement (FTA)...

Beyond basmati: Six Indian rice varieties known for their unique qualities

India is home to many traditional rice varieties; each...

Coal production rises 7.51% YoY, dispatch grows 17.34% in July

India's coal production grew 7.51% year-on-year in July 2026,...